Gilead to Acquire Oral IL-23R Inhibitor HCXT-2001 for IBD Pipeline
Gilead gains worldwide rights to investigational HCXT-2001 for a $1.27 billion upfront cash payment, strengthening its inflammation pipeline in IBD.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Reuters reported that Gilead Sciences has agreed to acquire HCXT-2001, an investigational oral IL-23R inhibitor. Under the terms of the deal, the company gains worldwide rights to the program that includes this drug. The upfront cash value of the transaction is $1.27 billion.
Gilead expects the deal to reduce its GAAP and non-GAAP earnings per share by $0.79 to $0.83 in the fourth quarter of 2026. The acquisition is aimed at widening the company's portfolio of treatments for inflammatory bowel disease.
why it matters
For the market this is mainly a targeted event, as the amount is in line with routine deals by large drugmakers. The main effect for investors is a temporary hit to reported earnings in late 2026 and a bet on a new IBD treatment that is still at the investigational stage.
market impact
Gilead shares: one-time costs temporarily weigh on Q4 2026 earnings per share
tags
instruments
sources
- Gilead To Acquire Investigational Oral Il-23R Inhibitor Hcxt-2001, Strengthening Its Inflammation Pipeline In Ibd — Reuters, 22 October 2026 at 22:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗